563
Views
6
CrossRef citations to date
0
Altmetric
Pharmacotherapy

Mepolizumab in adolescents with severe eosinophilic asthma not eligible for omalizumab: one center’s early clinical experience

, MBChB & , MD
Pages 521-524 | Received 22 Jan 2019, Accepted 03 Feb 2019, Published online: 22 Feb 2019

References

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.